Immune response to an intercalated enhanced inactivated polio vaccine/oral polio vaccine programme in israel : Impact on the control of poliomyelitis.
A combined enhanced inactivated polio vaccine (EIPV) and oral polio vaccine (OPV) programme was introduced in Israel in 1990, with the purpose of providing a solution to the persistent polio morbidity in spite of a 30 year long OPV programme.
The schedule comprised two doses of EIPV administered at the age of 2 and 4 months, intercalated with two doses of OPV at 4 and 6 months, followed by a reinforcing dose with the two vaccines simultaneously administered at 12 months.
The 5-year evaluation of the programme included : the assessment of clinical suspicions of polio, early immune response in successive cohorts administered the new schedule, dynamics of the immune profile in a cohort followed up to the age of 5, and monitoring of wild poliovirus excretion in sewage specimens collected in 25 permanent sites throughout Israel as well as from the Palestinian Authority.
No paralytic polio cases associated with a wild or vaccinal poliovirus strain were detected since the introduction of the programme.
At the age of 4 months, one week after administration of the second EIPV and first OPV dose, 100% seropositivity and high geometric mean titres (GMTs) of neutralizing antibody (NA) to the three vaccinal and to the wild poliovirus type I, responsible for the 1988 polio outbreak, were observed.
No change in percent of seropositivity occurred between the age of 6 and 12 months. (...)
Mots-clés Pascal : Poliovirus, Enterovirus, Picornaviridae, Virus, Nourrisson, Homme, Poliomyélite antérieure, Virose, Infection, Vaccin polyvalent, Souche inactivée, Immunogénicité, Immunité humorale, Persistance, Immunoprotection, Programme sanitaire, Eradication, Etude longitudinale, Epidémiologie, Prévalence, Israël, Asie
Mots-clés Pascal anglais : Poliovirus, Enterovirus, Picornaviridae, Virus, Infant, Human, Acute anterior poliomyelitis, Viral disease, Infection, Polyvalent vaccine, Inactivated strain, Immunogenicity, Humoral immunity, Persistence, Immunoprotection, Sanitary program, Eradication, Follow up study, Epidemiology, Prevalence, Israel, Asia
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 99-0057529
Code Inist : 002B05A02. Création : 31/05/1999.